Jazz Pharmaceuticals Q2 2024 Adj. EPS $5.30 Beats $4.77 Estimate, Sales $1.024B Beat $1.004B Estimate
Portfolio Pulse from Benzinga Newsdesk
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q2 2024 adjusted EPS of $5.30, beating the $4.77 estimate. Sales were $1.024 billion, surpassing the $1.004 billion estimate and marking a 6.97% increase from the same period last year.
July 31, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jazz Pharmaceuticals reported Q2 2024 adjusted EPS of $5.30, beating the $4.77 estimate by 11.11%. Sales were $1.024 billion, surpassing the $1.004 billion estimate and marking a 6.97% increase from the same period last year.
The company's strong performance in Q2 2024, with both EPS and sales beating analyst estimates, is likely to positively impact the stock price in the short term. The 6.97% year-over-year increase in sales further supports a positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100